Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program

References

• ApplegateWB2002Elderly patients’ adherence to statin therapyJAMA288495712132982
   PubMed Web of Science ®Google Scholar
• AuriacombeSPereJJ2002Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezilCurr Med Res Opin181293812094822
   PubMed Web of Science ®Google Scholar
• BalkrishnanR1998Predictors of medication adherence in the elderlyClin Ther20764719737835
   PubMed Web of Science ®Google Scholar
• BaratIAndreasenF2001Drug therapy in the elderly: what doctors believe and patients actually doBr J Clin Pharmacol516152211422022
   PubMed Web of Science ®Google Scholar
• BennerJSGlynnRJ2002Long-term persistence in use of statin therapy in elderly patientsJAMA2884556112132975
   PubMed Web of Science ®Google Scholar
• BergenJHuntG1998Six-month outcome following a relapse of schizophreniaAust N Z J Psychiatry328152210084346
   PubMed Web of Science ®Google Scholar
• BirksJ2006Cholinesterase inhibitors for Alzheimer’s diseaseCochrane Database Syst Rev1CD00559316437532
   PubMed Web of Science ®Google Scholar
• BullockRConnollyC2002Switching cholinesterase inhibitor therapy in Alzheimer’s disease--donepezil to rivastigmine, is it worth it?Int J Geriatr Psychiatry173288911921158
   PubMed Web of Science ®Google Scholar
• ChinMHGoldmanL1997Factors contributing to the hospitalization of patients with congestive heart failureAm J Public Health8764389146445
   PubMed Web of Science ®Google Scholar
• ChooPWRandCS1999Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapyMed Care378465710493464
   PubMed Web of Science ®Google Scholar
• ClarkCMKarlawishJH2003Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategiesAnn Intern Med1384001012614093
   PubMed Web of Science ®Google Scholar
• CleggABryantJ2001Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease: a rapid and systematic reviewHealth Technol Assess51137
   Google Scholar
• CleggABryantJ2002Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer’s disease. A systematic reviewInt J Technol Assess Health Care1849750712391943
   PubMed Web of Science ®Google Scholar
• ColNFanaleJE1990The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderlyArch Intern Med15084152327844
   PubMed Web of Science ®Google Scholar
• CoonsSJSheahanSL1994Predictors of medication noncompliance in a sample of older adultsClin Ther1611078205597
   PubMed Web of Science ®Google Scholar
• CramerJA1998Enhancing patient compliance in the elderly. Role of packaging aids and monitoringDrugs Aging127159467683
   PubMed Web of Science ®Google Scholar
• CurtissFR2005Does persistence with drugs for Alzheimer’s disease matter?J Manag Care Pharm11260215804211
   PubMedGoogle Scholar
• EmreM2002Switching cholinesterase inhibitors in patients with Alzheimer’s diseaseInt J Clin Pract Suppl127647212139369
   PubMedGoogle Scholar
• ErnstRLHayJW1994The US economic and social costs of Alzheimer’s disease revisitedAm J Public Health84126148059882
   PubMed Web of Science ®Google Scholar
• EwbankDC1999Deaths attributable to Alzheimer’s disease in the United StatesAm J Public Health899029987474
   PubMed Web of Science ®Google Scholar
• FillitHCummingsJ2000Practice guidelines for the diagnosis and treatment of Alzheimer’s disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer’s Disease (AD) Managed Care Advisory CouncilManag Care Interface1351610747691
   PubMedGoogle Scholar
• FillitHHillJ2004The economic benefits of acetylcholinesterase inhibitors for patients with Alzheimer disease and associated dementiasAlzheimer Dis Assoc Disord18Suppl 1S24915249845
   PubMed Web of Science ®Google Scholar
• FratiglioniL1993Epidemiology of Alzheimer’s disease. Issues of etiology and validityActa Neurol Scand Suppl1451708333250
   PubMedGoogle Scholar
• GeldmacherDS2003Long-term cholinesterase inhibitor therapy for Alzheimer’s disease: practical considerations for the primary care physicianPrim Care Companion J Clin Psychiatry5251915213795
   PubMedGoogle Scholar
• GeldmacherDSFrolichL2006Realistic expectations for treatment success in Alzheimer’s diseaseJ Nutr Health Aging104172917066215
   PubMed Web of Science ®Google Scholar
• GeldmacherDSProvenzanoG2003Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s diseaseJ Am Geriatr Soc519374412834513
   PubMed Web of Science ®Google Scholar
• GiacobiniE2000aCholinesterase inhibitor therapy stabilizes symptoms of Alzheimer diseaseAlzheimer Dis Assoc Disord14S31010850724
   PubMed Web of Science ®Google Scholar
• GiacobiniE2000bCholinesterase inhibitors stabilize Alzheimer diseaseNeurochem Res2511859011059792
   PubMed Web of Science ®Google Scholar
• GiacobiniE2001aDo cholinesterase inhibitors have disease-modifying effects in Alzheimer’s disease?CNS Drugs15859111460892
   PubMed Web of Science ®Google Scholar
• GiacobiniE2001bIs anti-cholinesterase therapy of Alzheimer’s disease delaying progressionAging132475411442306
   PubMedGoogle Scholar
• GiacobiniE2002Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer’s diseaseJ Neural Transm Suppl62181712456062
   PubMedGoogle Scholar
• GoldenAGPrestonRA1999Inappropriate medication prescribing in homebound older adultsJ Am Geriatr Soc479485310443855
   PubMed Web of Science ®Google Scholar
• GraySLMahoneyJE2001Medication adherence in elderly patients receiving home health services following hospital dischargeAnn Pharmacother355394511346058
   PubMed Web of Science ®Google Scholar
• GrutzendlerJMorrisJC2001Cholinesterase inhibitors for Alzheimer’s diseaseDrugs61415211217870
   PubMed Web of Science ®Google Scholar
• HebertLEBeckettLA2001Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050Alzheimer Dis Assoc Disord151697311723367
   PubMed Web of Science ®Google Scholar
• HebertLEScherrPA2003Alzheimer disease in the US population: prevalence estimates using the 2000 censusArch Neurol6011192212925369
   PubMed Web of Science ®Google Scholar
• HillJWFuttermanR2002The effect of donepezil therapy on health costs in a Medicare managed care planManag Care Interface15637011925682
   PubMedGoogle Scholar
• InglisF2002The tolerability and safety of cholinesterase inhibitors in the treatment of dementiaInt J Clin Pract Suppl127456312139367
   PubMedGoogle Scholar
• JackeviciusCAMamdaniM2002Adherence with statin therapy in elderly patients with and without acute coronary syndromesJAMA288462712132976
   PubMed Web of Science ®Google Scholar
• JannMW1998Pharmacology and clinical efficacy of cholinesterase inhibitorsAm J Health Syst Pharm155S2259809108
   PubMed Web of Science ®Google Scholar
• KloszewskaI2002Acetylcholinesterase inhibitors—beyond Alzheimer’s diseasePsychiatr Pol366 Suppl1334112647432
   PubMedGoogle Scholar
• LanctotKLHerrmannN2003Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysisCMAJ1695576412975222
   PubMed Web of Science ®Google Scholar
• LovemanEGreenC2006The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s diseaseHealth Technol Assess10iii-ivix-xi1160
   Web of Science ®Google Scholar
• LuscherTFVetterH1985Compliance in hypertension: facts and conceptsJ Hypertens, Suppl31S393916440
   PubMedGoogle Scholar
• MauskopfJAParamoreC2005Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settingsJ Manag Care Pharm112315115804207
   PubMedGoogle Scholar
• McDermottMMSchmittB1997Impact of medication nonadherence on coronary heart disease outcomes. A critical reviewArch Intern Med157192199308504
   PubMed Web of Science ®Google Scholar
• McDonaldHPGargAX2002Interventions to enhance patient adherence to medication prescriptions: scientific reviewJAMA28828687912472329
   PubMed Web of Science ®Google Scholar
• MonaneMMatthiasDM1998Improving prescribing patterns for the elderly through an online drug utilization review intervention: a system linking the physician, pharmacist, and computerJAMA2801249529786375
   PubMed Web of Science ®Google Scholar
• PatersonDLSwindellsS2000Adherence to protease inhibitor therapy and outcomes in patients with HIV infectionAnn Intern Med133213010877736
   PubMed Web of Science ®Google Scholar
• PsatyBMKoepsellTD1990The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockersJAMA263165371968518
   PubMed Web of Science ®Google Scholar
• RoccaWAHofmanA1991Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings. The EURODEM-Prevalence Research GroupAnn Neurol30381901952826
   PubMed Web of Science ®Google Scholar
• RoeCMAndersonMJ2002How many patients complete an adequate trial of donepezil?Alzheimer Dis Assoc Disord16495111882749
   PubMed Web of Science ®Google Scholar
• RogersSLFarlowMR1998A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study GroupNeurology50136459443470
   PubMed Web of Science ®Google Scholar
• RogersSLFriedhoffLT1996The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study GroupDementia72933038915035
   PubMedGoogle Scholar
• Sicras-MainarAVergaraJ2006Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer’s disease patients treated with donepezil, rivastigmine, galantamine and memantineRev Neurol434495317033976
   PubMed Web of Science ®Google Scholar
• SicrasARejas-GutierrezJ2004Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine]Rev Neurol39312615340887
   PubMed Web of Science ®Google Scholar
• SteinerJFProchazkaAV1997The assessment of refill compliance using pharmacy records: methods, validity, and applicationsJ Clin Epidemiol50105169048695
   PubMed Web of Science ®Google Scholar
• SullivanSDHazletTK1990Noncompliance with medication regimens and subsequent hospitalizations: A literature analysis and cost of hospitalization estimateJ Res Pharmac Econom21933
   Google Scholar
• TrinhNHHoblynJ2003Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysisJAMA289210612517232
   PubMed Web of Science ®Google Scholar
• TsuyukiRTBungardTJ2001Poor adherence with hypolipidemic drugs: a lost opportunityPharmacotherapy215768211349746
   PubMed Web of Science ®Google Scholar
• WilkinsonDGPassmoreAP2002A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer’s diseaseInt J Clin Pract56441612166542
   PubMed Web of Science ®Google Scholar
• ZuardEG2001New treatments for Alzheimer’s Disease: A reviewDrug benefit trends132740
   Google Scholar